PI-103

Catalog No.S1038

PI-103 Chemical Structure

Molecular Weight(MW): 348.36

PI-103 is a multi-targeted PI3K inhibitor for p110α/β/δ/γ with IC50 of 2 nM/3 nM/3 nM/15 nM in cell-free assays, less potent to mTOR/DNA-PK with IC50 of 30 nM/23 nM.

Size Price Stock Quantity  
In DMSO USD 134 In stock
USD 147 In stock
USD 270 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • (D) IGROV parental, shControl (two independent clones) and ShPKCiota (two independent clones) were treated with 5 μM GDC-0941 and 1.5 μM PI-103 for 24 hours and subjected to western blot analysis with the indicated antibodies. Each experiment was performed in triplicate.

    Oncogene, 2016, 35(19):2428-40. PI-103 purchased from Selleck.

    (A) MCF7 cells pre-treated with 100 nM siRNA for 72 h were re-seeded with normal growth media and grown overnight, then further transfected by 100nM of fresh siRNA. Twenty-(A) four hours after transfection, the cells were further treated with PI-103 for 24 h and the cell lysates were immunoblotted with the indicated antibodies. (B) Breast cancer cells carrying BRCA1 mutations were treated with 1 mM of PI-103 for 24h (left) or increasing amounts of PI-103 for 24 h (right). Cell lysates were analyzed by Western blotting with the indicated antibodies.

    Mol Carcinog 2012 52, 667-75 . PI-103 purchased from Selleck.

  • Knockdown of BRCA1 sensitizes cells to PI3K/AKT pathway inhibitors. MCF7 cells transfected with either BRCA1-siRNA or control-siRNA were treated with increasing amounts of inhibitors targeting the PI3K/AKT pathway for 48 h in triplicate. Viable cells were measured by MTT assay.

    Mol Carcinog 2012 ahead of print. PI-103 purchased from Selleck.

    We treated all of drugs in T47D which has a PI3KCA H1044R mutation with the concentration shown below for 1 hour and performed western blot analysis using antibodies to phospho-AKT(SERINE 472), and total AKT.

     

     

    Saraswati Sukumar of Johns Hopkins University School of Medicine PI-103 purchased from Selleck.

  • Breast cancer cells were pretreated with 100ng/ml EGF for 15 min and then treated with the indicated concentrations of PI-103 for 24 hours.

     

     

    Dr. Zhang of Tianjin Medical University. PI-103 purchased from Selleck.

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description PI-103 is a multi-targeted PI3K inhibitor for p110α/β/δ/γ with IC50 of 2 nM/3 nM/3 nM/15 nM in cell-free assays, less potent to mTOR/DNA-PK with IC50 of 30 nM/23 nM.
Features The first potent, synthetic mTOR inhibitor.
Targets
p110α [3]
(Cell-free assay)
p110β [3]
(Cell-free assay)
p110δ [3]
(Cell-free assay)
p110γ [3]
(Cell-free assay)
DNA-PK [3]
(Cell-free assay)
2 nM 3 nM 3 nM 15 nM 23 nM
In vitro

PI-103 potently inhibits both the rapamycin-sensitive (mTORC1) and rapamycin-insensitive (mTORC2) complexes of the protein kinase mTOR. [1] PI-103 inhibits constitutive and growth factor-induced PI3K/Akt, as well as mTORC1 activation. [2] In blast cells, PI-103 inhibits leukemic proliferation, the clonogenicity of leukemic progenitors and induces mitochondrial apoptosis, especially in the compartment containing leukemic stem cells. PI-103 inhibits p110α >200-fold more potently than p110β. PI-103 also potently blocks production of PI(3,4)P2 and PIP3 in adipocytes and PIP3 in myotubes. [2] PI-103 inhibits phosphorylation of Akt with an IC95 100-fold lower than that for LY294002. Strikingly, PI-103 completely protects animals from insulin-stimulated decline in blood glucose. PI-103 has additive proapoptotic effects with etoposide in blast cells and in immature leukemic cells. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SK-N-BE MkDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LIeFAuQCEQvF2= M{\peFI1NzR6L{eyJIg> Mom4bY5lfWOnczD0bY1mNSCjbnSgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRiaX7obYJqfGmxbjDvckBPSiClZXzsJIdzd3e2aB?= MmrHNlYzOjR4OEG=
SH-SY5Y MmP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjENmh5OC16IN88US=> NFP3bXozPC92OD:3NkBp Mo[xbY5lfWOnczD0bY1mNSCjbnSgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRiaX7obYJqfGmxbjDvckBPSiClZXzsJIdzd3e2aB?= NITweZAzPjJ{NE[4NS=>
SH-SY5Y  NU\hN283SXCxcITvd4l{KEG|c3H5 MX[xJO69VQ>? MVewMlUuOjRiaB?= MoXHd4Vve2m2aYrld{Bv\XW{b3LsZZN1d22jIHPlcIx{KHSxIHTvfI9zfWKrY3nuMYlv\HWlZXSgZZBweHSxc3nz MXqyOlIzPDZ6MR?=
G 35 SC NYqwcXdxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\vbo0xNjB3LUKwJO69VQ>? MYCyOE84OiCq M2T3Z2ROW09? NIi3bYRqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfGy7 Mo\aNlYyOjF{NUG=
G 38 SC M4XSPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7jNE4xPS1{MDFOwG0> NV7LTZZPOjRxN{KgbC=> M134RWROW09? M4qxb4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51dHl? MXOyOlEzOTJ3MR?=
G 40 SC MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV2wMlA2NTJyIN88US=> M{XRZVI1Nzd{IHi= NVLGcoR[TE2VTx?= NHHKWYZqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfGy7 NInqfVYzPjF{MUK1NS=>
G 35 DC MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnW5NE4xPS1{MDFOwG0> NGfJbXgzPC95MjDo M3LiTmROW09? Ml[ybY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBidmRidHnt[UBl\XCnbnTlcpRtgQ>? M4TnRlI3OTJzMkWx
G 38 DC NYqyUHU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTENE4xPS1{MDFOwG0> NV3uRoFIOjRxN{KgbC=> NFLRRZJFVVOR M3TMPYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51dHl? MkfhNlYyOjF{NUG=
G 40 DC M2Lacmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fNXlAvODVvMkCg{txO NH7nOG4zPC95MjDo NUXTVXJOTE2VTx?= MnzqbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBidmRidHnt[UBl\XCnbnTlcpRtgQ>? MWGyOlEzOTJ3MR?=
RD Mmf2RZBweHSxc3nzJGF{e2G7 M2jOTVEwOS53L{Kg{txO M1vYTFczKGh? M2HYNIlv\HWlZYOgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhiR1HOWFYy M{HlOlI2PzR7M{e4
TE381.T NHHnNplCeG:ydH;zbZMhSXO|YYm= MnvHNU8yNjVxMjFOwG0> MkPZO|IhcA>? Ml\pbY5lfWOnczDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCCJQV7UOlE> MYSyOVc1QTN5OB?=
RMS13 MkK3RZBweHSxc3nzJGF{e2G7 MWCxM|EvPS9{IN88US=> NV64WFRPPzJiaB?= M2f5XIlv\HWlZYOgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhiR1HOWFYy Mmf5NlU4PDl|N{i=
RH30  NXf3OJo1SXCxcITvd4l{KEG|c3H5 NFzU[Y0yNzFwNT:yJO69VQ>? MnzBO|IhcA>? MmrhbY5lfWOnczDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCCJQV7UOlE> Mn;ONlU4PDl|N{i=
VJ M{X5SWFxd3C2b4Ppd{BCe3OjeR?= NVK0W3p2OS9zLkWvNkDPxE1? NVezNZM3PzJiaB?= MlvkbY5lfWOnczDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCCJQV7UOlE> NVXmc3RtOjV5NEmzO|g>
HS578T NGTudHpE\WyuIG\pZYJqdGm2eTDBd5NigQ>? Ml[1NE0{KM7:TR?= M{PwfFczKGh? MkTxbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NGLUOVczPTd{MUSxPS=>
BT549 M{nTUGNmdGxiVnnhZoltcXS7IFHzd4F6 MXewMVMh|ryP NH32W4w4OiCq MXvpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NFvz[4kzPTd{MUSxPS=>
MDA-MB-231 NWm1[FQxS2WubDDWbYFjcWyrdImgRZN{[Xl? MmDQNE0{KM7:TR?= MXW3NkBp NI\pNINqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 MXGyOVczOTRzOR?=
MDA-MB-468 M4LZRmNmdGxiVnnhZoltcXS7IFHzd4F6 NFnqcHUxNTNizszN MYi3NkBp MVHpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NXvtNpNjOjV5MkG0NVk>
MDA-MB-436 M2rXbGNmdGxiVnnhZoltcXS7IFHzd4F6 NYnm[WF1OC1|IN88US=> M3j6VlczKGh? MV7pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NVnIbnhPOjV5MkG0NVk>
SUM149PT NHHYXnFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M1qwcFAuOyEQvF2= M{Oxb|czKGh? M1XR[YlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NXznRW45OjV5MkG0NVk>
MDA-MB-468 MlG5SpVv[3Srb36gRZN{[Xl? M2P0W|AvODFvMUCg{txO MkLrNlQhcA>? MorZ[I94dnKnZ4XsZZRmeyC2aHWgcIV3\Wy|IH;mJO6zNVS{Q2CxMEBkNU27YzDhcoQh[3mlbHnuJGUheHKxdHXpcpPDqA>? MljiNlU4OjF2MUm=
MDA-MB-231 MWnGeY5kfGmxbjDBd5NigQ>? MWSwMlAyNTFyIN88US=> M172RlI1KGh? MYrkc5dvemWpdXzheIV{KHSqZTDs[ZZmdHNib3[g{tIuXHKFUEGsJIMuVXmlIHHu[EBkgWOuaX6gSUBxem:2ZXnud:Kh NFT1WW0zPTd{MUSxPS=>
HS578T NFnrWoNHfW6ldHnvckBCe3OjeR?= MVewMlAyNTFyIN88US=> NY\oNZZNOjRiaB?= NHHZ[mZld3ewcnXneYxifGW|IITo[UBt\X[nbIOgc4Yh|rJvVILDVFEtKGNvTYnjJIFv\CCleXPsbY4hTSCycn;0[Ylve8Li NGHEcoMzPTd{MUSxPS=>
SW872 MWnGeY5kfGmxbjDBd5NigQ>? NVuwSFBsOC5yMT2wMlUh|ryP NF3kWpkzPCCq MXjy[YR2[2W|IFHLWEBxcG:|cHjvdplt[XSrb36gLJBCU1RrIHHu[EA1TUKSMTDwbI9{eGixconsZZRqd25iKIC0SWJROSliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XMEoB?= NWq2dY5tOjR4OUW2N|I>
SW982 MXnGeY5kfGmxbjDBd5NigQ>? M1TTblAvODFvMD61JO69VQ>? M1jJdVI1KGh? Mny2doVlfWOnczDBT3QheGixc4Doc5J6dGG2aX;uJEhxSUuWKTDhcoQhPEWEUEGgdIhwe3Cqb4L5cIF1cW:wIDjwOGVDWDFrIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{wrC= NVv1RWU4OjR4OUW2N|I>
SW872 M2HtemFxd3C2b4Ppd{BCe3OjeR?= MnnyNE4xOS1yLkWg{txO NVq0SlUyPDhiaB?= NGOzSpJqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5 NXK4T4c6OjR4OUW2N|I>
SW982 MnTpRZBweHSxc3nzJGF{e2G7 NYnlNHRiOC5yMT2wMlUh|ryP M{PERVQ5KGh? MlvzbY5lfWOnczDhdI9xfG:|aYOg[I9{\SCmZYDlcoRmdnSueR?= MWqyOFY6PTZ|Mh?=
AGS HG MkXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTBwNkigxtEhOC5yM{Gg{txO NFu2fGUzPDV7N{S3PC=>
AGS LG NV[5dII1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDkeFU{UUN3ME2wMlA2KMLzIECuNFAyKM7:TR?= MnnQNlQ2QTd2N{i=
HGC27 HG MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\1c4VJUUN3ME2wMlM5KMLzIECuNFIzKM7:TR?= MmfYNlQ2QTd2N{i=
HGC27 LG NGq4U2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzQVY9KSzVyPUCuNFIhyrFiMD6wNFQh|ryP MVGyOFU6PzR5OB?=
MKN45 HG NXnMN|FlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTmNmFKSzVyPUGuNFEhyrFiMD6wOVEh|ryP NEDXR3IzPDV7N{S3PC=>
MKN45 LG Ml[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\ZWmlEPTB;MD64O{DDuSByLkCzNEDPxE1? NFLj[2kzPDV7N{S3PC=>
NUGC4 HG MnOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;6b2lEPTB;MUSuNEDDuSB|LkmxN{DPxE1? MUmyOFU6PzR5OB?=
NUGC4 LG MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkK0TWM2OD1zND6wJOKyKDVwM{KxJO69VQ>? M3XoOVI1PTl5NEe4
A549 MoPBSpVv[3Srb36gRZN{[Xl? NWTjT2pKOC5{NT:wMlUwOSEQvF2= NInXPJkzPCCq NWj4SG5lcW6qaXLpeJMhSWu2IIDoc5NxcG:{eXzheIlwdiC|bHnnbJRtgQ>? NGfCW|QzPDN3MUSyOS=>
H460 NUnM[5p6TnWwY4Tpc44hSXO|YYm= Mmm1NE4zPS9yLkWvNUDPxE1? M4DmOVI1KGh? NIrwSGNqdmirYnn0d{BCc3RicHjvd5Bpd3K7bHH0bY9vKHOuaXfoeIx6 MonHNlQ{PTF2MkW=
H661 NFLxSJJHfW6ldHnvckBCe3OjeR?= NX;4dJZyOC5{NT:wMlUwOSEQvF2= MnHLNlQhcA>? NV7TSFEycW6qaXLpeJMhSWu2IIDoc5NxcG:{eXzheIlwdiC|aXfubYZq[2GwdHz5 NFu5SpEzPDN3MUSyOS=>
SAS NF\4RYZHfW6ldHnvckBCe3OjeR?= MXuwMlI2NzBwNT:xJO69VQ>? M2\oS|I1KGh? MXTpcohq[mm2czDBb5QheGixc4Doc5J6dGG2aX;uJJNq\26rZnnjZY51dHl? M3HQSVI1OzVzNEK1
UT5 NVPIbWZZTnWwY4Tpc44hSXO|YYm= NHrLOWYxNjJ3L{CuOU8yKM7:TR?= NXSzc2ZWOjRiaB?= NYfhOo96cW6qaXLpeJMhSWu2IIDoc5NxcG:{eXzheIlwdiC|aXfubYZq[2GwdHz5 Ml;ONlQ{PTF2MkW=
FaDu NVrLZmJGTnWwY4Tpc44hSXO|YYm= M2DZdlAvOjVxMD61M|Eh|ryP NWPNbI0yOjRiaB?= Mm\0bY5pcWKrdIOgRYt1KHCqb4PwbI9zgWyjdHnvckB{cWewaX\pZ4FvfGy7 NGXhfYszPDN3MUSyOS=>
RD MULBdI9xfG:|aYOgRZN{[Xl? M2LYc|EwOS53L{Kg{txO NXXKeHlUPzJiaB?= NV3YTXB6TE2VTx?= MkLVbY5lfWOnczDjZZNx[XOnLXTldIVv\GWwdDDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCCXT{GyOi=> MWSyN|Y5PDl{NR?=
TE671 NXPaZYhbSXCxcITvd4l{KEG|c3H5 MojENU8yNjVxMjFOwG0> NV\FUZEyPzJiaB?= M2rUcmROW09? M4P1OYlv\HWlZYOgZ4F{eGG|ZT3k[ZBmdmSnboSgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhiVV:xNlY> M3Xq[lI{Pjh2OUK1
RH30  NVjr[mNDSXCxcITvd4l{KEG|c3H5 NY\uPYZOOS9zLkWvNkDPxE1? NWP4fI9rPzJiaB?= M3nUNmROW09? MV7pcoR2[2W|IHPhd5Bie2VvZHXw[Y5l\W62IHHwc5B1d3OrczDjc41jcW6nZDD3bZRpKFWRMUK2 NX3tS4FTOjN4OES5NlU>
RMS13 NUfrNIh7SXCxcITvd4l{KEG|c3H5 NIrWRWYyNzFwNT:yJO69VQ>? NILQOoo4OiCq NH;YdIVFVVOR NXXhdG86cW6mdXPld{Bk[XOyYYPlMYRmeGWwZHXueEBieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDDVU|EzPg>? MXqyN|Y5PDl{NR?=
SUM149PT MVXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NFfLTFkxNjNizszN MWi3NkBp MlXm[Y5p[W6lZYOgZ5l1d3SxeHnjJIVn\mWldIOgc4YhWEl|Sz;BT3QheGG2aIfhfUBqdmirYnn0c5J{ MVqyN|YxOTB5NB?=
MDA-MB-468 NWHSd2lHS2WubDDWbYFjcWyrdImgRZN{[Xl? M3\vVlAvOyEQvF2= NUCzdJJSPzJiaB?= NF34fFFmdmijbnPld{BkgXSxdH;4bYMh\W[oZXP0d{Bw\iCSSUPLM2FMXCCyYYToe4F6KGmwaHnibZRwenN? M3vNcVI{PjBzMEe0
MDA-MB-231 MljER4VtdCCYaXHibYxqfHliQYPzZZk> MUGwMlMh|ryP NEizeVc4OiCq NUHCeJQx\W6qYX7j[ZMh[3m2b4TvfIlkKGWoZnXjeJMhd2ZiUFmzT{9CU1RicHH0bJdigSCrbnjpZol1d3K| M1rveVI{PjBzMEe0
SY5Y MVfGeY5kfGmxbjDBd5NigQ>? NIXzXWgyNjVxMj61M|Uh|ryP M3G5VFI1KGh? NVW5[FhIcW6mdXPld{BIOcLiY3XscE1kgWOuZTDhdpJme3RiYX7kJIFxd3C2b4Ppdy=> NVXJUI5nOjN|N{izOFE>
SKNBE(2c) NUG1PFRMTnWwY4Tpc44hSXO|YYm= M1ux[FEvPS9{LkWvOUDPxE1? NWHafGl5OjRiaB?= NWLvcW5IcW6mdXPld{BIOcLiY3XscE1kgWOuZTDhdpJme3RiYX7kJIFxd3C2b4Ppdy=> MlSyNlM{Pzh|NEG=
RD NWHkbld6SXCxcITvd4l{KEG|c3H5 MmnUN{DDvU1? M3nSW|EzKGh? MYXEUXNQ NFi4SYx{\W6|aYTpfoV{KFKGIHPlcIx{KHSxIFTPXE1qdmS3Y3XkJIFxd3C2b4Ppdy=> NX;SUFh7OjN|MEC4NFk>
TP5014 NWDZSZo4SXCxcITvd4l{KEG|c3H5 NFPMZ40{KML3TR?= M1r3XVEzKGh? M{[3[mROW09? M{XqR5NmdnOrdHn6[ZMhWkRiY3XscJMhfG9iRF;YMYlv\HWlZXSgZZBweHSxc3nz MV6yN|MxODhyOR?=
HT1080 M2Lw[2Fxd3C2b4Ppd{BCe3OjeR?= NF3CbI4{KML3TR?= NVHzNm1TOTJiaB?= M1zxTWROW09? MVLz[Y5{cXSrenXzJHJFKGOnbHzzJJRwKESRWD3pcoR2[2WmIHHwc5B1d3Orcx?= Ml\DNlM{ODB6MEm=
A549 MoT5SpVv[3Srb36gRZN{[Xl? MkfhNE0{NjNizszN MkGxO|IhcA>? Mme2bY5lfWOnczDjc41xdGW2ZTDkc5dvemWpdXzheIlwdiCxZjDwRWtV NUfLPJpJOjN{NUm1PVE>
HCC827 Mk\uSpVv[3Srb36gRZN{[Xl? MXSwMVMvOyEQvF2= NV;kNI5jPzJiaB?= NHjtO|VqdmS3Y3XzJINwdXCuZYTlJIRwf26{ZXf1cIF1cW:wIH;mJJBCU1R? MlvENlMzPTl3OUG=
H3122 MoLRSpVv[3Srb36gRZN{[Xl? M2f6dlAuOy5|IN88US=> MkLmO|IhcA>? MUnpcoR2[2W|IHPvcZBt\XSnIHTve45z\We3bHH0bY9vKG:oIIDBT3Q> NXLNRZpxOjN{NUm1PVE>
TALL-1 NULjZphwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\INgKBkc7:TR?= NVn2N|FvPyCm MVnk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> NV7RXJNwOjNyM{iyO|M>
HPB-ALL NGH5SFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zNU|HjiIoQvF2= MkO0O{Bl MUnk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> NETUN3gzOzB|OEK3Ny=>
DND41 NEXn[FdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTTb2FDOeLCid88US=> MYW3JIQ> MX3k[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> NVvwV|JiOjNyM{iyO|M>
SUP-T1 NIK2OWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjkNgKBkc7:TR?= NVHrVFRlPyCm MnLy[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 M1:4UFI{ODN6Mkez
PEER MmHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUmx5qCK|ryP M4LaSFch\A>? MXzk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> NVLtN4U4OjNyM{iyO|M>
ALL-SIL NXjv[XlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{n3R|HjiIoQvF2= NV;GZ5dQPyCm NUG2V5FR\GWlcnXhd4V{KHSqZTDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7 MmfmNlMxOzh{N{O=
KE37 M1nH[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXaVFBNOeLCid88US=> NWHG[m5EPyCm M3Xy[4Rm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>? NIf2WWozOzB|OEK3Ny=>
Karpas-45 NGHFUIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXpTlZHOeLCid88US=> NEXPXXg4KGR? M33QXoRm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>? MmHHNlMxOzh{N{O=
RPMI-8402 M1j5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTxNgKBkc7:TR?= NXSyToNsPyCm NUn0bpdM\GWlcnXhd4V{KHSqZTDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7 M1fCNVI{ODN6Mkez
Jurkat MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX2x5qCK|ryP NHrvfpk4KGR? MXrk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> NYS2N3pJOjNyM{iyO|M>
MOLT-4 MnuxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrFZms6OeLCid88US=> MYi3JIQ> M1;obYRm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>? NH;ZU4QzOzB|OEK3Ny=>
PF-382 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3S5PVHjiIoQvF2= MkD1O{Bl MnrC[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 Mo\SNlMxOzh{N{O=
CCRF-CEM Mnm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlv2NgKBkc7:TR?= MmDyO{Bl MXjk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> M4HScFI{ODN6Mkez
LOUCY M{HCdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{X0NlHjiIoQvF2= NX3MNZhlPyCm M1K2SIRm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>? Ml7PNlMxOzh{N{O=
MOLT-16 NXPQbGdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;6ZlHjiIoQvF2= MkfZO{Bl NWe2dZhi\GWlcnXhd4V{KHSqZTDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7 M2DqWFI{ODN6Mkez
MM1S MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzm[nUxNTJizszN Mk\vNlQhcA>? MoLZTWM2OD1yLkWg{txO M17EPFIzQDJ7MkO0
NCI-H929 MkXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DLO|AuOiEQvF2= NXS5SohUOjRiaB?= M2W1XGlEPTB;MD6yOUDPxE1? MknZNlI5Ojl{M{S=
KMS12-BM  NEPxdmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXSNE0zKM7:TR?= M1nJWVI1KGh? NVr0cZJGUUN3MP-8olIh|ryP MUmyNlgzQTJ|NB?=
MDA-MB-436 NV;LeXA{TnWwY4Tpc44hSXO|YYm= Mnf4NUDPxE1? M{PBNFI1KGh? M33KfpJm\HWlZYOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCDS2S= NG[zVGYzOjR6OEW5NC=>
SUM149PT NWjXTFdMTnWwY4Tpc44hSXO|YYm= MoDsNUDPxE1? MVmyOEBp MkOwdoVlfWOnczD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEGNVB?= M4PqN|IzPDh6NUmw
SUM1315MO2 MXHGeY5kfGmxbjDBd5NigQ>? Ml:3NUDPxE1? M{TFTVI1KGh? MXTy[YR2[2W|IITo[UBxcG:|cHjvdplt[XSrb36gc4YhSUuW MlLVNlI1QDh3OUC=
HCC1937 M33hZ2Z2dmO2aX;uJGF{e2G7 NXHY[XVROSEQvF2= MnfzNlQhcA>? NYLOOJFjemWmdXPld{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFHLWC=> NFOwR24zOjR6OEW5NC=>
HCC827 M1jKR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVywMVMh|ryP NWTtcWZGPzJiaB?= NYPKe4puUUN3ME2wMlMh|ryP NHXy[5YzOTJ{MES3OC=>
PC-9  MnjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnVNE0{KM7:TR?= M4jlXVczKGh? NWixPYZJUUN3ME2wMlgh|ryP NEP1SGwzOTJ{MES3OC=>
LN229 NV\GdFZCTnWwY4Tpc44hSXO|YYm= MkPrNUDPxE1? MkHwOFghcA>? MVrpcoR2[2W|IHH1eI9xcGGpb4PvcYUh\m:{bXH0bY9v MlGxNlExPjJ7OUO=
U87 NFLL[VZHfW6ldHnvckBCe3OjeR?= MoHkNUDPxE1? NVTlZYxoPDhiaB?= M1r0fYlv\HWlZYOgZZV1d3CqYXfvd49u\SCob4LtZZRqd25? NYjkSXRlOjFyNkK5PVM>
U373 NXjhSHd3TnWwY4Tpc44hSXO|YYm= NILYXHIyKM7:TR?= NVrPUmRPPDhiaB?= M2[ydIlv\HWlZYOgZZV1d3CqYXfvd49u\SCob4LtZZRqd25? MWOyNVA3Ojl7Mx?=
SF767 NEXPVWFHfW6ldHnvckBCe3OjeR?= MkHrNUDPxE1? MXS0PEBp Mn;6bY5lfWOnczDheZRweGijZ3;zc41mKG[xcn3heIlwdg>? NWPabHM6OjFyNkK5PVM>
Mel-Juso Mm\QR4VtdCCYaXHibYxqfHliQYPzZZk> MV:wMlAy6oDVMUFihKnPxE1? MXS3NkBp MYjpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 MoLYNlExPDh5OEW=
518A2  NUHLNXFHS2WubDDWbYFjcWyrdImgRZN{[Xl? NFP4SJIxNjBz4pETNVDjiIoQvF2= MlflO|IhcA>? NX3jc3FGcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= MUOyNVA1QDd6NR?=
Mel-Juso  MkLsSpVv[3Srb36gRZN{[Xl? MmOyNE4xODIkgKOx5qCK|ryP MofmNlQhcA>? MX7zeZBxemW|c3XzJJBpd3OyaH;yfYxifGmxbjDv[kBxcG:|cHjheIllgWxiaX7vd4l1d2xiMz3rbY5ie2ViZH;3cpN1emWjbTD0ZZJo\XS| M2LtVVIyODR6N{i1
518A2 MnL4SpVv[3Srb36gRZN{[Xl? MYCwMlAxOeLCk{JihKnPxE1? M2rKdFI1KGh? NE\0fI1{fXCycnXzd4V{KHCqb4PwbI9zgWyjdHnvckBw\iCyaH;zdIhifGmmeXygbY5we2m2b3ygN{1scW6jc3Wg[I94dnO2cnXhcUB1[XKpZYTz M2fYbVIyODR6N{i1
PC3  M{PFS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofjNlRp MlrxS2k2OMLiPTCxNFAhdk1? MlO3NlA2PTFyNkG=
U87MG MkTISpVv[3Srb36gRZN{[Xl? MofGNE4yNTFizszN MYKyOQKBkWkEoB?= MY\EUXNQ MlTlbY5pcWKrdIOgVGk{Uy2vZXTpZZRm\CC|aXfuZYxqdmd? MVuxPVY{OzZ6Mx?=
U138MG M4joOmZ2dmO2aX;uJGF{e2G7 NGfUVosxNjFvMTFOwG0> NVnzd|NoOjUkgJnoxsA> MX\EUXNQ MV\pcohq[mm2czDQTVNMNW2nZHnheIVlKHOrZ37hcIlv\w>? NVf1cndPOTl4M{O2PFM>
U118MG NVzGVJpVTnWwY4Tpc44hSXO|YYm= MXiwMlEuOSEQvF2= NWfv[JVwOjUkgJnoxsA> MUPEUXNQ MlnvbY5pcWKrdIOgVGk{Uy2vZXTpZZRm\CC|aXfuZYxqdmd? Mnq3NVk3OzN4OEO=
U87MG NUDRbHdCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XaPGlEPTB;MD6xOEDPxE1? M3nsXVE6PTh2MkK3
IGROV-1 M2HlSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;IbFdKSzVyPUCuNFYh|ryP MlXkNVk2QDR{Mke=
DETROIT562 NWnzWHJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnSxTWM2OD1yLkGzJO69VQ>? MXexPVU5PDJ{Nx?=
PC3  NIXUb3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnJbJdlUUN3ME2wMlExKM7:TR?= NUDsSnJxOTl3OESyNlc>
SKOV-3 NGPjfXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zJ[2lEPTB;MD6xNkDPxE1? MlL2NVk2QDR{Mke=
HUVEC M2nlfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV74R3U2UUN3ME2wMlA5KM7:TR?= NICxToMyQTV6NEKyOy=>
UCH-1  NW\F[nc6TnWwY4Tpc44hSXO|YYm= NEnoeVAxNTVizszN MnO3bY5pcWKrdIOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCkb4ToJGFMXCCjbnSgcXRQWiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NIe2[pAyQTV{OES0NS=>
UCH-1  NHvZempIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPS[5IxNjBzLUGwJO69VQ>? NXnLSm5KPiCm NUfoOpB[cW6qaXLpeJMheHKxbHnm[ZJifGmxbjDkc5NmKGSncHXu[IVvfGy7 NXvX[lhCOTl3Mki0OFE>
UCH-1  NV;Od5pDSXCxcITvd4l{KEG|c3H5 M3HRTVAvOS1zMDFOwG0> MmToNlQhcA>? NYrFe4dsTE2VTx?= MWHpcoR2[2W|IHHwc5B1d3Orcx?= NFSxZpQyQTV{OES0NS=>

... Click to View More Cell Line Experimental Data

In vivo When tumors reach 50-100 mm3, animals are randomized and treated with vehicle or PI-103. PI-103 exhibits significant activity, decreasing average tumor size by 4-fold after 18 days. [2] Mice treated with PI-103 have no obvious signs of toxicity premorbidly (based on body weight, food and water intake, activity, and general exam) or at necropsy. Treated tumors display decreased levels of phosphorylated Akt and S6, consistent with blockade of p110α and mTOR. PI-103 treatment is cytostatic to glioma xenografts. [2]

Protocol

Kinase Assay:[3]
+ Expand

Enzyme Assays:

Phosphatidylinositide 3-kinase inhibitory activity was determined using a scintillation proximity assay in the presence of 1 μmol/L ATP. Inhibition of mTOR protein kinase was determined using a TR-FRET-based LanthaScreen method from Invitrogen. Compounds were assayed at a maximum concentration of 10 μmol/L in the presence of 1 μmol/L ATP, and IC50 values were determined using GraphPad Prism software.
Cell Research:[2]
+ Expand
  • Cell lines: U87MG cells
  • Concentrations: 0.5 μM
  • Incubation Time: 24 hours
  • Method: U87MG cells are treated with PI-103 for 24 hours. Cell death is quantified by colorimetric determination of LDH activity using a cytotoxicity detection kit. Percentage of cell death (mean of three 12-well plates per experimental point) is calculated [(experimental value- low control)/(high control -low control) × 100], where the low-control cells are DMSO treated and high-control cells are Triton treated (1% Triton X-100, 30 min, 37 °
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: 6- to 12-week-old Balbc nu/nu mice bearing U87MG:ΔEGFR cells
  • Formulation: 50% DMSO
  • Dosages: 5 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 24 mg/mL (68.89 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
1% DMSO+30% polyethylene glycol+1% Tween 80
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 348.36
Formula

C19H16N4O3

CAS No. 371935-74-9
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy PI-103 | PI-103 supplier | purchase PI-103 | PI-103 cost | PI-103 manufacturer | order PI-103 | PI-103 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID